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Abstract 
Background 
Hyperglycemia often occurs in premature, very low birthweight infants (VLBW) due to 
immaturity of endogenous regulatory systems and the stress of their condition. 
Hyperglycemia in neonates has been linked to increased morbidities and mortality and occurs 
at increasing rates with decreasing birthweight. In this cohort, the emerging use of insulin to 
manage hyperglycemia has carried a significant risk of hypoglycemia. The efficacy of blood 
glucose control using a computer metabolic system model to determine insulin infusion rates 
was assessed in very-low-birth-weight infants. 
Methods 
Initial short-term 24-hour trials were performed on 8 VLBW infants with hyperglycemia 
followed by long-term trials of several days performed on 22 infants. Median birthweight was 
745 g and 760 g for short-term and long-term trial infants, and median gestational age at birth 
was 25.6 and 25.4 weeks respectively. Blood glucose control is compared to 21 retrospective 
patients from the same unit who received insulin infusions determined by sliding scales and 
clinician intuition. This study was approved by the Upper South A Regional Ethics 
Committee, New Zealand (ClinicalTrials.gov registration NCT01419873). 
Results 
Reduction in hyperglycemia towards the target glucose band was achieved safely in all cases 
during the short-term trials with no hypoglycemic episodes. Lower median blood glucose 
concentration was achieved during clinical implementation at 6.6 mmol/L (IQR: 5.5 – 8.2 
mmol/L, 1,003 measurements), compared to 8.0 mmol/L achieved in similar infants 
previously (p < 0.01). No significant difference in incidence of hypoglycemia during long-
term trials was observed (0.25% vs 0.25%, p = 0.51). Percentage of blood glucose within the 
4.0 – 8.0 mmol/L range was increased by 41% compared to the retrospective cohort (68.4% 
vs 48.4%, p < 0.01). 
Conclusions 
A computer model that accurately captures the dynamics of neonatal metabolism can provide 
safe and effective blood glucose control without increasing hypoglycemia. 
Trial Registration 
ClinicalTrials.gov registration NCT01419873 
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Background 
Hyperglycemiaoccurs in many premature neonates. The threshold for hyperglycemia differs 
between studies, but prevalence of hyperglycemia has been reported in 57% of extremely low 
birthweight (ELBW) infants [1] and 32–86% of very low birthweight (VLBW) infants 
[2,3].An increasing body of literature links hyperglycemia to worsened outcomes in 
premature neonates, but there have been no studies of sufficient power to demonstrate 
whether hyperglycemia itself is harmful, or is merely a reflection of disease severity. 
Loss of glucose regulation can be caused by clinical stress, leading to a rise in hepatic 
gluconeogenesis as well as a reduction in insulin sensitivity [4]. At the same time, premature 
VLBW infants have reduced ability to produce insulin [2]; defective beta-cell processing of 
pro-insulin (which is 10–16 times less active than insulin) to insulin [5]; an inability to 
suppress hepatic glucose production in response to glucose infusion [6]; and, finally, a 
decreased uptake of glucose secondary to a limited mass of insulin-sensitivity tissues such as 
muscle and adipose tissue [7]. 
Neonatal units will differ in their approach to the management of hyperglycemia. There is no 
strict definition for hyperglycemia, but, it is generally regarded as a blood glucose (BG) 
exceeding 10 mmol/L [8]. There is no consensus on the threshold for intervention, which 
reflects the lack of reliable evidence upon which to base management decisions [8]. Glucose 
restriction can be used to control high blood glucose levels [9]. However, this approach also 
deprives the neonate of crucial energy required to promote growth [2]. A small number of 
prospective trials have used insulin infusions to treat hyperglycemia and/or promote growth 
[10-18]. Positive outcomes of insulin infusion have included reduced proteolysis, improved 
glucose tolerance, increased IGF-I levels and improved caloric intake and weight gain. The 
American Academy of Paediatrics has supported the use of insulin since 1985[19]. However, 
larger trials of insulin usage in both neonates and adults have been confounded by increased 
rates of hypoglycemia. Recently, the NIRTURE trial used a fixed dose of insulin on day 1and 
modulated glucose infusions versus standard care and found an increased rate of 
hypoglycemia in the treatment group. This studywas stopped early [10]. There have also only 
been two other small randomized controlled trials with a total of 47 patients that have 
compared different managementoptions forhyperglycemia in this group of patients [12,20]. 
All reported neonatal insulin infusion trials have used either protocols that fixed insulin 
dosing to weight or other factors [21], or clinician judgment to determine insulin infusion 
rates. It is well reported that preterm infants can show great variety in terms of sensitivity to 
exogenous insulin infusions [2]. This suggests that the use of insulin will increase the risk of 
hypoglycemia, unless variability in sensitivity to insulin is explicitly taken into account. 
Thus, an insulin dosing strategy to achieve both goals of reduced blood glucose levels and 
safety from hypoglycemiashould a) estimate a patient’s particular level of response to insulin, 
b) account for any potential changes in sensitivity to insulin over time, and c) adapt dosing 
accordingly to cater for individual patients. 
Model-based systems attempt to control BG by using a mathematical representation of the 
glucose-insulin system to quantify a patient’s insulin sensitivity and track changes over time 
[22,23]. Databases of sensitivity to insulin can be created using retrospective data from 
babies that have received insulin [22]. This information can be interrogated using stochastic 
tools to observe how the level of response to insulin in babies varies both between patients 
and over time [24]. Forecasts of potential changes in sensitivity to insulin can be generated 
for a patient at a particular point in time to compute the likely impact on BG levels for a 
given prospective dose of insulin [24]. Thus, the dose of insulin can be optimized to balance 
the requirements of lowering blood glucose levels whilst reducing the risk of hypoglycemia 
[25,26]. 
Blood glucose control using model-based methods has been applied successfully in limited 
adult clinical trials [27] and large-scale clinical implementation [28], which reduced both 
blood glucose levels and hypoglycemia using a combined insulin and nutrition protocol [29]. 
The success of this model-basedsystem in adults suggests that such an approach could also 
provide a useful tool for metabolic management in neonates. This study presents the first trial 
of model-based glycemic control in this unique neonatal patient population. 
Methods 
Study population 
This study was approved by the Upper South A Regional Ethics Committee, New Zealand 
(ClinicalTrials.gov registration NCT01419873). Infants who met eligibility criteria were 
recruited between August 2008 and June 2011 from the neonatal intensive care unit (NICU) 
at Christchurch Women’s Hospital. Inclusion criteria werebirthweight < 1,500 g, blood 
glucose concentration ≥ 10 mmol/L and a clinical decision to commence an insulin infusion. 
Infants who were not expected to survive were excluded. Written parental consent was 
obtained for each study participant during the pilot study phase. Data from a retrospective 
cohort of 21 infants that received insulin in 2005–2006 in the same NICU, before the 
introduction of the computer-based system, were collected for comparison. 
Clinical protocols 
This study was conducted in two parts: a series of short-term trials that intensively monitored 
infants to assess safety and effectiveness; and long-term trials that implemented the system 
into daily clinical practice. The study period during short-term trials was up to 24 hours, and 
most patients enrolled were already receiving insulin infusions. Blood glucose concentrations 
were measured every 1 to 3 hours (maximum 12 measurements per day). Long-term trials 
covered the entire period of insulin usage for an infant and blood glucose concentrations were 
generally measured at 2–4 hour intervals at the attending clinician’s discretion. The same 
computer system was used for both parts of the study. 
The insulin infusion rate was adjusted as determined by the model-based controller after each 
BG measurement. Occasionally, blood gas measurements were taken for other clinical 
reasons and provided additional blood glucose concentration data. This extra data was also 
used to update the insulin infusion rate. Blood was drawn from an in-situ arterial line if 
present, otherwise from capillary samples and analyzed with a Bayer 850 blood gas analyzer 
(Bayer AG, Leverkusen, Germany). 
The blood glucose concentration profile, together with the insulin and nutrition data, was 
used by the computer algorithm to determine insulin infusion rates to reach the target range 
of 4 to 7 mmol/L (Figure 1). Model “insulin sensitivity” was estimated from the clinical data 
in real-time to identify the current metabolic state of the infant [22]. The controller used the 
fitted insulin sensitivity value to iterate through several possible insulin infusion rates and 
forecast a blood glucose concentration 1 to 4 hours ahead, depending on the time of the next 
planned measurement. The insulin infusion rate that was predicted to achieve a blood glucose 
concentration closest to the target was selected. 
Figure 1 Controller implementation overview 
A stochastic insulin sensitivity model [24] was used to provide confidence limits around the 
forecasted blood glucose concentration, and the selected insulin infusion rate was adjusted to 
ensure that the lower 5% probability limit of the forecasted blood glucose concentration 
was > 4 mmol/L. Further details on the model identification, control methodology and 
stochastic modeling of insulin sensitivity are published elsewhere [24,26,30]. 
The computer system uses entered information on insulin rates, dextrose input rates from IV 
and enteral sources and prior blood glucose concentrations to determine the insulin sensitivity 
level of the patient [30]. This insulin sensitivity parameter represents the level of glycemic 
response the infant has been exhibiting to exogenous insulin over the last few hours. Thus, 
lower observed insulin sensitivity would result in recommendations of relatively higher 
insulin rates and vice-versa. A stochastic model is used to determine the potential changes in 
sensitivity to insulin in the upcoming hours based on observed changes in sensitivity to 
insulin in retrospective data [24]. The current BG, rates of dextrose inputs, level of sensitivity 
to insulin and forecasted changes in sensitivity to insulin are used by the computer model to 
select an insulin rate that balances the goals of achieving BG within the target range whilst 
limiting the potential for hypoglycemia [25,31]. Incorporating information about nutrition 
inputs allows insulin dosages to be scaled accordingly to provide control for infants receiving 
higher and lower amounts of calories. 
Infants received most nutrition via parenteral solutions containing 10–12.5% dextrose. 
Several infants also received expressed breast milk (EBM), and some infants received 
morphine and dobutamine infusions prepared using 5% dextrose. All sources of glucose and 
any hour-to-hour changes were considered by the model-based controller algorithm when 
recommending insulin infusion rates. 
Insulin was given via intravenous lines using Alaris CC pumps (Alaris, San Diego, 
California, USA) as a continuous infusion. The concentration of insulin was [5 x weight (kg)] 
U made up to 20 mL with 0.9% saline solution to achieve a concentration of 0.25 U/kg/mL. 
Insulin tubing was flushed with this solution to minimize subsequent adsorption of insulin to 
the tubing [32]. New insulin infusion rates were determined after every BG measurement and 
a neonatal clinician chartedevery change in insulin infusion rate before adjusting the pump, 
which is standard practice. The maximum allowable insulin infusion rate was restricted to 0.5 
U/kg/hr for safety. 
The retrospective group received blood glucose control using insulin infusions using the 
sliding scale presented in Table 1 as a guideline. Actual insulin rates used in these patients 
were left to the discretion of the attending clinician, who could deviate from the suggested 
scale if desired. Thus, there was no explicit BG target, but the clinical practice of this unit 
was to aim to maintain BG within the 5 – 8 mmol/L range, and results from these patients are 
reported to provide context to represent typical clinical practice in thus unit prior to the 
introduction of model-based control. 
Table 1 Retrospective control insulin sliding scale.Insulin started at 0.2 
ml/hr = (0.05units/kg/hr using standard insulin dilution) 
BG Insulin adjustment 
> 20 mmol/L 0.4 ml/hr (0.1 U/kg/hr) 
15 – 20 mmol/L 0.3 ml/hr (0.075 U/k/hr) 
10 – 15 mmol/L 0.2 ml/hr (0.05 U/kg/hr) 
< 5 mmol/L STOP 
Manipulations were recommended based on BG concentration. 
Results 
Eight infants were included in the short-term trial with median birth gestation of 25.6 weeks 
and median birthweight of 745grams. Infants were enrolled at 1 to 9 days of age (Table 2). 
Insulin was already being used on 6 of the 8 short-term trial patients before the 24-hour trial 
period, and the median time of insulin usage before these trials was 7.4 hours. The 27 long-
term trials were performed on 22 patients with median birth gestation of 25.4 weeks and 
median birthweight of 760 grams. The retrospective cohort comprised 21 patients with 
median gestation of 26.6 weeks and median birthweight of 845 grams. Babies with 
birthweight between 1,000 – 1,500 grams formed a minority of the patients in these cohorts, 
with 4 babies in the long-term study, 2 babies in the retrospective cohort and none of the 
babies in the short-term study in this weight range. 
Table 2 Clinical details of study populations 
 Short-term 
(N = 8) 
Long-term 
(N = 22) 
Retrospective 
(N = 21) 
Gestational age at birth 
(weeks) 
25.6 [24.9 – 26.4] 25.4 [25.0 – 26.8] 26.6 [25.4 – 27.7] 
Weight at birth (grams) 745 [681 – 814] 760 [601 – 925] 845 [800 – 904] 
Age at start of trial (days) 6.6 [3.6 – 7.7] 3.6 [1.5 – 6.4] n/a 
Data presented as median [inter-quartile range] 
Clinical blood glucose results during the study are presented in Table 3. Linear interpolation 
between BG measurements was used to provide hourly estimates of BG concentrations. Thus, 
percentages of measurements within reported ranges represent an estimate of the time spent 
within the specified range to ensure an equal and fair comparison across datasets with 
different measurement frequencies. The control system was used for a total of 226 hours in 
short-term trials and 3,168 hours in long-term trials, and 3,571 hours of control were 
available for the retrospective cohort.A mixture of arterial and capillary BG samples were 
used in the long-term and retrospective data sets as presented in Table 3. Four long-term 
patients and two retrospective patients had multiple episodes of insulin usage during their 
neonatal intensive care stay. The whole-cohort median BG during long-term trials was 6.6 
mmol/L,which was within the target 4 – 7 mmol/L range. By comparison, the retrospective 
median BG level was a more conservative 8.0 mmol/L(p < 0.01, Mann–Whitney test). The 
short-term trials spent a larger proportion of time reducing blood glucose from hyperglycemia 
levels, so the higher median of 7.4 mmol/L was expected, and blood glucose results are not 
directly comparable between short-term trials and either the long-term or retrospective 
results. 
Table 3 Clinical blood glucose control variables during trials and comparison with 
retrospective control 
Whole cohort statistics Short-term Long-term Retrospective 
Number of episodes 8 22 21 
Total hours 226 hours 3168 hours 3571 hours 
Number of BG measurements 117 1003 1091 
BG sampling site: arterial/capillary 100%/0% 27%/73% 45%/55% 
BG median [IQR] (mmol/L) 7.4 [6.2 - 9.4] 6.6 [5.5 - 8.2] 8.0 [6.6 - 9.4] 
% BG within 4.0 - 7.0 mmol/L 40.9 53.7 29.5 
% BG within 4.0 - 8.0 mmol/L 63.9 68.4 48.4 
% BG > 10 mmol/L 22.6 11.7 19.2 
% BG < 4.0 mmol/L 0.9 4.0 2.7 
% BG < 3.0 mmol/L 0.0 0.5 0.4 
% BG < 2.7 mmol/L 0.00 0.25 0.25 
Median insulin rate [IQR] (U/kg/hr) 0.058 [0.038 - 0.107] 0.033 [0.028 - 0.040] 0.025 [0.010 - 0.045] 
Median glucose rate [IQR] 
(mg/kg/min) 
8.2 [7.1 - 9.4] 7.9 [6.1 – 9.3] 8.4 [6.3 - 9.1] 
Per-patient statistics (presented as median [IQR]) 
Number of BG measurements 15.0 [13.0 - 17.5] 27.0 [15.0 - 44.8] 36.0 [21.0 - 54.0] 
Initial BG (mmol/L) 11.4 [7.5 - 12.3] 11.4 [9.4 – 13.4] 8.9 [5.7 – 9.9] 
Time between measurements (hours) 2.0 [2.0 - 2.1] 3.0 [2.8 - 3.3] 3.2 [2.6 - 4.0] 
%BG within 4.0-7.0 mmol/L 41.4 [14.4 - 60.8] 60.4 [38.2 – 72.7] 29.6 [20.4 - 38.5] 
%BG within 4.0-8.0 mmol/L 58.8 [48.3 - 75.9] 74.1 [57.7 - 84.2] 47.7 [42.9 - 55.7] 
%BG < 4.0 mmol/L [IQR] 0.0 [0.0 - 0.0] 4.8 [3.1 - 9.3] 2.8 [0.0 - 5.4] 
%BG < 3.0 mmol/L [IQR] 0.0 [0.0 - 0.0] 0.0 [0.0 - 2.0] 0.0 [0.0 - 0.2] 
%BG < 2.7 mmol/L [IQR] 0.0 [0.0 - 0.0] 0.0 [0.0 - 0.7] 0.0 [0.0 - 0.0] 
Dextrose rate (mg/kg/min) 1.2 [0.3 - 1.6] 5.2 [0.6 - 14.0] 4.8 [1.9 - 6.7] 
EBM (mL/kg/day) 4.6 [1.0 - 5.7] 15.8 [2.3 - 41.9] 16.7 [5.4 – 27.2] 
Patients that received EBM 6 (75%) 19 (86%) 18 (86%) 
Proportion of dextrose via EBM (%) 1.2 [0.3 - 1.7] 11.0 [1.5 - 21.4] 5.5 [1.9 - 7.2] 
Insulin rate (U/kg/hr) 0.058 [0.046 - 0.088] 0.033 [0.028 - 0.040] 0.025 [0.010 - 0.045] 
Insulin sensitivity x 10
-3
 
(L/[mU.min]) 
1.28 [0.48 – 1.86] 1.73 [1.25 - 2.65] 1.93 [1.40 – 2.58] 
Blood glucose (BG) results are resampled hourly 
Safety from hypoglycemia (BG < 2.7 mmol/L) was present despite the lower achieved blood 
glucose levels during the trials. No hypoglycemic events were recorded during the short-term 
trials, and there was no significant difference in the low incidence of hypoglycemia between 
the long-term trials and retrospective control dataat a rate of 0.25% of resampled 
measurements each (p = 0.51, Fisher’s Exact test). 
The percentage of BG within the computer control target 4.0 – 7.0 mmol/L range was 82% 
higher for the long-term cohort compared to retrospective control (53.7% vs. 29.5%, p <0.01, 
Chi-squared test). The wider 4.0 – 8.0 mmol/L band covers covers both computer-control and 
retrospective target ranges, and was 41% higher for computer control(68.4% vs. 48.4%, 
p < 0.01, Chi-squared test). Increased time within target ranges was consistent across patients, 
where the per-patient medians of BG within the 4.0-7.0 mmol/L and 4.0-8.0 mmol/L bands 
were consistently higher for model-based control (60.4% vs. 29.6% for 4.0 – 7.0 mmol/L 
band, p <0.01, Mann–Whitney test and 74.1% vs. 47.7% for 4.0 – 8.0 mmol/L band, p <0.01, 
Mann–Whitney test). 
Infants during the trials showed large variations in response to insulin. The 90% range of per-
patient median insulin sensitivity showed a 6.6x spread during the short-term trials and 
greater than 10x spread during the long-term trials. Thus, a particular infant may exhibit an 
over 10x stronger response to insulin than another infant. Additionally, the hour-to-hour 
changes may be even larger than the comparison of median sensitivity levels. Clinical 
dextrose and EBM usage also showed significant variation between patients, reflecting 
individual clinical condition and thus a wide range of insulin infusion rates were used by the 
control system. 
Figure 2 graphically presents the blood glucose concentrations and quantified insulin 
sensitivity during the trials. The short-term trials showed a uniform response of blood glucose 
approaching the target band over the approximately 24-hour trials. Over this time period 
insulin sensitivity was generally relatively constant, yet each patient had a unique value. The 
long-term blood glucose results showed a general tightening and approach to the target band 
with less incidence of blood glucose greater than 10 mmol/L compared to retrospective data. 
The long-term insulin sensitivity results showed significantly greater variability observed 
over the longer time scale. Additionally, any periods of BG below the target band during the 
long-term clinical implementation trials were generally brief and resolved quickly. 
Figure 2 BG concentration and estimated insulin sensitivity during short-term, long-
term computerized insulin dosing trials and retrospective control. For the short-term 
trials each line in the top row of plots represents blood glucose concentration for each patient. 
The shaded region represents the 4–7 mmol/L target band. Each line in the bottom row of 
plots represents the evolution of sensitivity to exogenous insulin for each patient. For the 
long-term and retrospective patients summary boxplots are presented for each day of control 
The model-based insulin dosing application was entirely run by clinical staff during the long-
term study. The median time between BG measurements per patient during the long-term 
study was similar to retrospective patients on insulin at 3.0 versus 3.2 hours respectively. The 
system has been accepted for on-going use in this neonatal unit. 
Discussion 
This study compared computer-based control of BG using insulin infusions against clinical 
control before the introduction of the system. The retrospective clinical control group had a 
generally higher target than the computer-controlled group. It is completely feasible that even 
though model-based control targeted a lower BG range it may have had no difference on BG 
concentrations compared to the previous methods of BG control. The results presented 
indicate that the model-based system achieved lower BG levels and greater time of BG spent 
in the desired target range, without excessive hypoglycemia. 
Hyperglycemia has been linked to worsening outcomes for premature infants [1,33-36], but 
there is currently no best-practice approach to its management. Great inter-patient 
heterogeneity is a hallmark of neonatal glucose metabolism making safe, adequate control 
difficult [2,13]. Even within this relatively small study population a 10-fold spread of insulin 
sensitivity was computed during long-term trials. Additionally, the inter-patient variation in 
sensitivity to insulin observed in the short-term trials, presented in Figure 2, highlight this 
wide range of response between individuals. Thus, fixed insulin protocols based on weight or 
other patient parameters are not likely to accurately account for this level of inter-patient 
variability, and an adaptive protocol, as presented here, may provide better, safer control. 
Model-based control provides real-time identification of insulin sensitivity, and its evolution 
with time. However, identification of insulin sensitivity relies on the availability of blood 
glucose concentration measurements. One to four hourly measurements were used in this 
study, based on simulation results [26], as a compromise between accurate metabolic 
identification and nursing/patient burden, magnified in premature neonates with limited blood 
volumes. Frequent glucose sampling has been shown to be an important precursor for tight 
glycemic control [26]. Some insulin infusion studies in premature neonates used longer 
measurement and intervention intervals of up to 6 hours [10], which may have contributed to 
the difficulty of achieving glycemic control [37]. Continuous glucose monitoring systems 
may help in this regard to prevent hypoglycemia and limit excursions into hyperglycemia by 
providing greater information to quantify insulin sensitivity and respond faster to changes in 
patient condition. 
Clinically, babies were observed to occasionally have periods of rapid change in sensitivity to 
insulin. Both increases and decreases in the level of insulin sensitivity were seen and often 
could not be linked to significant changes in any other routinely measured clinical variable 
during this time. Thus, it is possible that there were changes in some aspect of glucose 
metabolism that is not typically measured during neonatal intensive care. This example 
demonstrates robustness of the control system to account for clinically un-measurable and un-
modeled effects. 
The targets for glucose control vary widely between clinical units [8]. A blood glucose 
concentration less than 2.7 mmol/L may increase the risk of long term neurological 
deficiencies, and is often cited as a limit for hypoglycemia [38]. However, the precise upper 
limit for clinically desirable blood glucose concentration is still under debate [2,8,39]. In 
particular, the 8.0 mmol/L median for retrospective control may have satisfied the attending 
clinicians at the time and prevented attempts to lower the blood glucose further. The target 
range of 4–7 mmol/L selected for this study was a relatively conservative choice, reflecting 
the nature of these pilot trials as the first model-based study performed in premature 
neonates. The blood glucose target for model-based control can be readily adjusted and could 
thus provide a method to target specific ranges of blood glucose concentrations, without 
increasing the risk of hypoglycemia. This methodology could be utilized in a future 
randomized controlled trial to assess the efficacy of insulin infusions for glucose control 
whilst avoiding the complication of increased rates of hypoglycemia in the tightly controlled 
group. 
The risk of hypoglycemia is often cited as a barrier to large-scale adoption of glycemic 
control by insulin infusions, especially as most neonatal hypoglycemia appears to be 
asymptomatic [40]. Some studies [10,41] found the incidence of hypoglycemia was 
significantly higher in infants receiving insulin therapy than in controls. In contrast, the 
results presented in this study and the adult SPRINT system developed from model-based 
control show a frequency of hypoglycemia similar to that seen with retrospective hospital 
control protocols [28]. Thus, the potential for model-based control to reduce BG levels 
without increasing hypoglycemia by accounting for patient variability may add another 
element to the discussion of ideal BG targets. 
This study compared pilot trial results to retrospective data. Changes in clinical management 
of these infants over time may have influenced the degree of metabolic variability observed 
during the trials versus historical data and thus influence relative improvement in glucose 
control with this system. However, the low incidence of hypoglycemia is an absolute metric 
independent of any comparison cohort. This result suggests there is a possibility to use 
insulin for glycemic control without creating significant risk of hypoglycemia, provided 
dosing is adapted to individual, time-varying patient condition. 
The stochastic model employed in this study is built from a whole-cohort perspective using 
data from the 21 patient retrospective group [24]. Thus, the forecasts achieve the desired 
prediction spread over the whole-cohort. However, the degree of variability in insulin 
sensitivity is patient-specific and may be linked to other clinical and diagnostic variables. 
Further clinical data and studies may identify patients at different stages of development or 
with different clinical issues. Individualized stochastic models may provide tighter forecast 
bands by identifying the levels of glycemic stability for individual patient. 
The long-term study included two infants with gestational age of 23 weeks at birth. These 
infants were significantly younger than the remainder of the study populations and displayed 
significant resistance to insulin and persistent hyperglycemia despite insulin infusions, 
resulting in a clinical decision to reduce the dextrose concentration of their parenteral 
nutrition infusions. This result suggests that in some infants the use of insulin alone may not 
be enough to fully bring glycemia into control without significantly increasing the 
hypoglycemiarisk, and that adjusting other infusions affecting the glucose-insulin system 
may be necessary in these cases. 
The goal of this study was to assess the efficacy of model-based insulin dosing for the control 
of glycemia, as opposed to eliciting the direct anabolic effects of insulin. The model-based 
approach can naturally modulate dextrose and insulin intake in tandem to meet nutrition 
goals, while controlling glycemia to allow more prospective neonatal metabolic management. 
This approach has already been demonstrated in adult critical care studies [27-29]. Finally, a 
significant range of dextrose infusions were used in these infants, and thus accounting for the 
total glucose load is vital to accurately choose appropriate insulin infusion rates across 
multiple patients. 
Conclusions 
This study presents the first data using an adaptive, model-based predictive controller for 
insulin infusion, designed to incorporate the unique metabolic state of the neonate. The 
controller was used to achieve glycemic control in30premature infants weighing < 1,500 g 
and reduce hyperglycemia compared to retrospective hospital control without increasing 
hypoglycemia risk. Significant inter-patient variation in insulin sensitivity was observed, and 
the controller adequately managed this to regulate blood glucose concentrations. This study 
tested the safety of a computer system for blood glucose control and may be useful for future 
studies to investigate the potential impact of tight glycemic control on outcomes. 
Abbreviations 
BG, Blood Glucose; IQR, Inter-Quartile Range; VLBW, Very Low BirthWeight 
Competing interests 
The authors declare they have no competing interests with respect to this study. 
Author contributions 
ALC, JGC, CGP and JL developed the model-based control system and clinical software. 
ALC performed the data collection and results analysis AML was responsible for clinical 
implementation ion Christchurch Women’s Neonatal Department. GMS provided additional 
implementation support at Christchurch Hospital. All authors read and approved the final 
manuscript. 
Acknowledgements 
Financial support for ALC provided by the Foundation for Research in Science and 
Technology, New Zealand. The funding body had no role in the study design, in the 
collection, analysis, and interpretation of data; in the writing of the manuscript; and in the 
decision to submit the manuscript for publication. 
References 
1. Hays SP, Smith B, Sunehag AL: Hyperglycemia Is a Risk Factor for Early Death and 
Morbidity in Extremely Low Birth-Weight Infants. Pediatrics 2006, 118(5):1811–1818. 
2. Cowett RM, Farrag HM: Selected principles of perinatal-neonatal glucose metabolism. 
SeminNeonatol 2004, 9(1):37–47. 
3. Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, Vanhole C, Palmer CR, Ong K, 
VanWeissenbruch M, Midgley P, Thompson M, Thio M, et al: Prevalence and 
determinants of hyperglycemia in very low birth weight infants: cohort analyses of the 
NIRTURE study. J Pediatr 2010, 157(5):715–719. e711-713. 
4. McCowen KC, Malhotra A, Bistrian BR: Stress-induced hyperglycemia. Crit Care Clin 
2001, 17(1):107–124. 
5. Mitanchez-Mokhtari D, Lahlou N, Kieffer F, Magny J-F, Roger M, Voyer M: Both 
Relative Insulin Resistance and Defective Islet {beta}-Cell Processing of Proinsulin Are 
Responsible for Transient Hyperglycemia in Extremely Preterm Infants. Pediatrics 
2004, 113(3):537–541. 
6. Cowett RM, Oh W, Schwartz R: Persistent glucose production during glucose infusion 
in the neonate. J Clin Invest 1983, 71(3):467–475. 
7. Raney M, Donze A, Smith JR: Insulin infusion for the treatment of hyperglycemia in 
low birth weight infants: examining the evidence. Neonatal Netw 2008, 27(2):127–140. 
8. Alsweiler JM, Kuschel CA, Bloomfield FH: Survey of the management of neonatal 
hyperglycaemia in Australasia. J Paediatr Child Health 2007, 43(9):632–635. 
9. Hemachandra AH, Cowett RM: Neonatal Hyperglycemia. Pediatr Rev 1999, 20(7):16e–
24e. 
10. Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, Vanhole C, Palmer CR, van 
Weissenbruch M, Midgley P, Thompson M, Thio M, Cornette L, et al: Early Insulin 
Therapy in Very-Low-Birth-Weight Infants. N Engl J Med 2008, 359(18):1873–1884. 
11. Agus MS, Javid PJ, Ryan DP, Jaksic T: Intravenous insulin decreases protein 
breakdown in infants on extracorporeal membrane oxygenation. J PediatrSurg 2004, 
39(6):839–844. 
12. Collins JW Jr, Hoppe M, Brown K, Edidin DV, Padbury J, Ogata ES: A controlled trial 
of insulin infusion and parenteral nutrition in extremely low birth weight infants with 
glucose intolerance. J Pediatr 1991, 118(6):921–927. 
13. Vaucher YE, Walson PD, Morrow G 3rd: Continuous insulin infusion in 
hyperglycemic, very low birth weight infants. J PediatrGastroenterolNutr 1982, 1(2):211–
217. 
14. Binder ND, Raschko PK, Benda GI, Reynolds JW: Insulin infusion with parenteral 
nutrition in extremely low birth weight infants with hyperglycemia. J Pediatr 1989, 
114(2):273–280. 
15. Thabet F, Bourgeois J, Guy B, Putet G: Continuous insulin infusion in hyperglycaemic 
very-low-birth-weight infants receiving parenteral nutrition. ClinNutr 2003, 22(6):545–
547. 
16. Ostertag S, Jovanovic L, Lewis B, Auld P: Insulin pump therapy in the very low birth 
weight infant. Pediatrics 1986, 78(4):625–630. 
17. Kanarek KS, Santeiro ML, Malone JI: Continuous infusion of insulin in hyperglycemic 
low-birth weight infants receiving parenteral nutrition with and without lipid emulsion. 
J Parenter Enteral Nutr 1991, 15(4):417–420. 
18. Beardsall K, Ogilvy-Stuart AL, Frystyk J, Chen JW, Thompson M, Ahluwalia J, Ong KK, 
Dunger DB: Early elective insulin therapy can reduce hyperglycemia and increase 
insulin-like growth factor-I levels in very low birth weight infants. J Pediatr 2007, 
151(6):611–617. 
19. American Academy of Pediatrics Committee on Nutrition: Nutritional needs for low-
birth-weight infants. Pediatrics 1985, 75:976–986. 
20. Meetze W, Bowsher R, Compton J, Moorehead H: Hyperglycemia in extremely- low-
birth-weight infants. Biol Neonate 1998, 74(3):214–221. 
21. Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, Ahluwalia JS, Vanhole C, Palmer C, 
Midgley P, Thompson M, Cornette L, Weissenbruch M, et al: A randomised controlled 
trial of early insulin therapy in very low birth weight infants, "NIRTURE" (neonatal 
insulin replacement therapy in Europe). BMC Pediatr 2007, 7:29. 
22. Le Compte A, Chase JG, Russell G, Lynn A, Hann C, Shaw G, Wong XW, Blakemore A, 
Lin J: Modeling the glucose regulatory system in extreme preterm infants. Comput 
Methods Programs Biomed 2010, 102(3):253–266. 
23. Chase JG, Le Compte A, Preiser JC, Shaw G, Penning S, Desaive T: Physiological 
modeling, tight glycemic control, and the ICU clinician: what are models and how can 
they affect practice? Annals of Intensive Care 2011, 1(1):11. 
24. Le Compte AJ, Lee DS, Chase JG, Lin J, Lynn A, Shaw GM: Blood glucose prediction 
using stochastic modeling in neonatal intensive care. IEEE Trans Biomed Eng 2010, 
57(3):509–518. 
25. Le Compte AJ, Chase JG, Lynn A, Hann CE, Shaw GM, Lin J: Development of blood 
glucose control for extremely premature infants. Comput Methods Programs Biomed 
2011, 102(2):181–191. 
26. Le Compte A, Chase JG, Lynn A, Hann C, Shaw G, Wong X-W, Lin J: Blood Glucose 
Controller for Neonatal Intensive Care: Virtual Trials Development and First Clinical 
Trials. J Diabetes SciTechnol 2009, 3(5):1066–1081. 
27. Chase J, Shaw GM, Wong XW, Lotz T, Lin J, Hann CE: Model-based glycaemic 
control in critical care - a review of the state of the possible. Biomedical Signal 
Processing and Control 2006, 1(1):3–21. 
28. Chase JG, Shaw G, Le Compte A, Lonergan T, Willacy M, Wong X-W, Lin J, Lotz T, 
Lee D, Hann C: Implementation and evaluation of the SPRINT protocol for tight 
glycaemic control in critically ill patients: a clinical practice change. Crit Care 2008, 
12(2):R49. 
29. Lonergan T, LeCompte A, Willacy M, Chase JG, Shaw GM, Wong XW, Lotz T, Lin J, 
Hann CE: A simple insulin-nutrition protocol for tight glycemic control in critical 
illness: development and protocol comparison. Diabetes TechnolTher 2006, 8(2):191–206. 
30. Hann CE, Chase JG, Lin J, Lotz T, Doran CV, Shaw GM: Integral-based parameter 
identification for long-term dynamic verification of a glucose-insulin system model. 
Comput Methods Programs Biomed 2005, 77(3):259–270. 
31. Evans A, Le Compte A, Tan CS, Ward L, Steel J, Pretty CG, Penning S, Suhaimi F, Shaw 
GM, Desaive T, et al: Stochastic targeted (STAR) glycemic control: design, safety, and 
performance. J Diabetes SciTechnol 2012, 6(1):102–115. 
32. Hewson M, Nawadra V, Oliver J, Odgers C, Plummer J, Simmer SK: Insulin infusions 
in the neonatal unit: Delivery variation due to adsorption.J Paed Child. Health 2000, 
36(3):216–220. 
33. Garg R, Agthe AG, Donohue PK, Lehmann CU: Hyperglycemia and retinopathy of 
prematurity in very low birth weight infants. J Perinatol 2003, 23(3):186–194. 
34. Kao LS, Morris BH, Lally KP, Stewart CD, Huseby V, Kennedy KA: Hyperglycemia 
and morbidity and mortality in extremely low birth weight infants. J Perinatol 2006, 
26(12):730–736. 
35. Alaedeen DI, Walsh MC, Chwals WJ: Total parenteral nutrition-associated 
hyperglycemia correlates with prolonged mechanical ventilation and hospital stay in 
septic infants. J PediatrSurg 2006, 41(1):239–244. 
36. Heimann K, Peschgens T, Kwiecien R, Stanzel S, Hoernchen H, Merz U: Are recurrent 
hyperglycemic episodes and median blood glucose level a prognostic factor for 
increased morbidity and mortality in premature infants </=1500 g? J Perinat Med 2007, 
35(3):245–248. 
37. Chase JG, Le Compte AJ, Suhaimi F, Shaw GM, Lynn A, Lin J, Pretty CG, Razak N, 
Parente JD, Hann CE, et al: Tight glycemic control in critical care - The leading role of 
insulin sensitivity and patient variability: A review and model-based analysis. Comput 
Methods Programs Biomed 2011, 102(2):156–171. 
38. Cornblath M, Hawdon JM, Williams AF, Aynsley-Green A, Ward-Platt MP, Schwartz R, 
Kalhan SC: Controversies regarding definition of neonatal hypoglycemia: suggested 
operational thresholds. Pediatrics 2000, 105(5):1141–1145. 
39. Ogilvy-Stuart AL, Beardsall K: Management of hyperglycaemia in the preterm infant. 
Arch Dis Child Fetal Neonatal Ed 2010, 95(2):F126–F131. 
40. Lucas A, Morley R, Cole TJ: Adverse neurodevelopmental outcome of moderate 
neonatal hypoglycaemia. Br Med J 1988, 297(6659):1304–1308. 
41. Vlasselaers D, Milants I, Desmet L, Wouters PJ, Vanhorebeek I, van den Heuvel I, 
Mesotten D, Casaer MP, Meyfroidt G, Ingels C, et al: Intensive insulin therapy for patients 
in paediatric intensive care: a prospective, randomised controlled study. Lancet 2009, 
373(9663):547–556. 


	
	
		
	


		

		


		

	
	

	




	
	

				
	
 !		


		
	

	



	
	

∀ 

	
∀ 
∀ #		
Figure 1
0 5 1 0 1 5 2 0 2 5
0
2
4
6
8
1 0
1 2
1 4
1 6
1 8
2 0
B G :  S h o r t - t e r m
T i m e  [ h o u r s ]
BG
 
[m
m
ol
/L
]
Figure 2
